Drugs for Non-small Cell Lung Cancer Market Report

Global and Region Drugs for Non-small Cell Lung Cancer Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 01, 2022
  • PAGES：232
  • REPORT CODE：GMM970127
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Drugs for Non-small Cell Lung Cancer market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Drugs for Non-small Cell Lung Cancermarket, defines the market attractiveness level of Drugs for Non-small Cell Lung Cancer market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Drugs for Non-small Cell Lung Cancer industry, describes the types of Drugs for Non-small Cell Lung Cancer market, the applications of major players and the market size, and deeply analyzes the current situation of the global Drugs for Non-small Cell Lung Cancer market and the development prospects and opportunities of Drugs for Non-small Cell Lung Cancer industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Drugs for Non-small Cell Lung Cancer market in Chapter 13.

    By Player:

    • Menarini

    • CytRx

    • Exelixis

    • Sanofi

    • Apotex

    • Cerulean Pharma

    • GlaxoSmithKline

    • Hikma Pharmaceuticals

    • Alchemia

    • Cipla

    • CellAct Pharma

    • Fresenius Kabi

    • BioMarin Pharmaceutical

    • Eli Lilly

    • Amgen

    • Kyowa Hakko Kirin

    • Hospira

    • Karyopharm Therapeutics

    • Genentech

    • Bristol-Myers Squibb

    • Ligand Pharmaceuticals

    • Intas Pharmaceuticals

    • Curis

    • Ziopharm Oncology

    • Cornerstone Pharmaceuticals

    By Type:

    • Radiofrequency Ablation (RFA)

    • Radiation Therapy

    • Chemotherapy

    • Targeted Therapies

    • Immunotherapy

    By End-User:

    • Hospitals

    • Clinics

    • Other

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Drugs for Non-small Cell Lung Cancer Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Drugs for Non-small Cell Lung Cancer Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Drugs for Non-small Cell Lung Cancer Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Drugs for Non-small Cell Lung Cancer Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Drugs for Non-small Cell Lung Cancer Market Analysis and Outlook to 2022

    • 7.1 Global Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)

    • 7.2 United States Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)

    • 7.3 Europe Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)

    • 7.4 China Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)

    • 7.5 Japan Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)

    • 7.6 India Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)

    • 7.7 South Korea Drugs for Non-small Cell Lung Cancer Consumption (2017-2022)

    8 Region and Country-wise Drugs for Non-small Cell Lung Cancer Market Analysis and Outlook to 2028

    • 8.1 Global Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)

    • 8.2 United States Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)

    • 8.3 Europe Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)

    • 8.4 China Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)

    • 8.5 Japan Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)

    • 8.6 India Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)

    • 8.7 South Korea Drugs for Non-small Cell Lung Cancer Consumption Forecast (2022-2028)

    9 Global Drugs for Non-small Cell Lung Cancer Market Outlook by Types and Applications to 2022

    • 9.1 Global Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Radiofrequency Ablation (RFA) Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Radiation Therapy Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Chemotherapy Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Targeted Therapies Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Immunotherapy Consumption and Growth Rate (2017-2022)

    • 9.2 Global Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Global Drugs for Non-small Cell Lung Cancer Market Outlook by Types and Applications to 2028

    • 10.1 Global Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Radiofrequency Ablation (RFA) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Targeted Therapies Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    11 Global Drugs for Non-small Cell Lung Cancer Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Drugs for Non-small Cell Lung Cancer Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Drugs for Non-small Cell Lung Cancer Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Drugs for Non-small Cell Lung Cancer Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Drugs for Non-small Cell Lung Cancer Market Competitive Analysis

    • 14.1 Menarini

      • 14.1.1 Menarini Company Details

      • 14.1.2 Menarini Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Menarini Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.2 CytRx

      • 14.2.1 CytRx Company Details

      • 14.2.2 CytRx Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 CytRx Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.3 Exelixis

      • 14.3.1 Exelixis Company Details

      • 14.3.2 Exelixis Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Exelixis Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.4 Sanofi

      • 14.4.1 Sanofi Company Details

      • 14.4.2 Sanofi Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Sanofi Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.5 Apotex

      • 14.5.1 Apotex Company Details

      • 14.5.2 Apotex Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Apotex Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.6 Cerulean Pharma

      • 14.6.1 Cerulean Pharma Company Details

      • 14.6.2 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.7 GlaxoSmithKline

      • 14.7.1 GlaxoSmithKline Company Details

      • 14.7.2 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.8 Hikma Pharmaceuticals

      • 14.8.1 Hikma Pharmaceuticals Company Details

      • 14.8.2 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.9 Alchemia

      • 14.9.1 Alchemia Company Details

      • 14.9.2 Alchemia Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Alchemia Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.10 Cipla

      • 14.10.1 Cipla Company Details

      • 14.10.2 Cipla Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Cipla Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.11 CellAct Pharma

      • 14.11.1 CellAct Pharma Company Details

      • 14.11.2 CellAct Pharma Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 CellAct Pharma Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.12 Fresenius Kabi

      • 14.12.1 Fresenius Kabi Company Details

      • 14.12.2 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.13 BioMarin Pharmaceutical

      • 14.13.1 BioMarin Pharmaceutical Company Details

      • 14.13.2 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.14 Eli Lilly

      • 14.14.1 Eli Lilly Company Details

      • 14.14.2 Eli Lilly Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Eli Lilly Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.15 Amgen

      • 14.15.1 Amgen Company Details

      • 14.15.2 Amgen Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Amgen Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.16 Kyowa Hakko Kirin

      • 14.16.1 Kyowa Hakko Kirin Company Details

      • 14.16.2 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.17 Hospira

      • 14.17.1 Hospira Company Details

      • 14.17.2 Hospira Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Hospira Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.18 Karyopharm Therapeutics

      • 14.18.1 Karyopharm Therapeutics Company Details

      • 14.18.2 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.18.3 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.19 Genentech

      • 14.19.1 Genentech Company Details

      • 14.19.2 Genentech Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.19.3 Genentech Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.20 Bristol-Myers Squibb

      • 14.20.1 Bristol-Myers Squibb Company Details

      • 14.20.2 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.20.3 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.21 Ligand Pharmaceuticals

      • 14.21.1 Ligand Pharmaceuticals Company Details

      • 14.21.2 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.21.3 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.22 Intas Pharmaceuticals

      • 14.22.1 Intas Pharmaceuticals Company Details

      • 14.22.2 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.22.3 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.23 Curis

      • 14.23.1 Curis Company Details

      • 14.23.2 Curis Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.23.3 Curis Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.24 Ziopharm Oncology

      • 14.24.1 Ziopharm Oncology Company Details

      • 14.24.2 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.24.3 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Product and Service

    • 14.25 Cornerstone Pharmaceuticals

      • 14.25.1 Cornerstone Pharmaceuticals Company Details

      • 14.25.2 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

      • 14.25.3 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Drugs for Non-small Cell Lung Cancer

    • Figure Drugs for Non-small Cell Lung Cancer Picture

    • Table Global Drugs for Non-small Cell Lung Cancer Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Drugs for Non-small Cell Lung Cancer Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Drugs for Non-small Cell Lung Cancer Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Drugs for Non-small Cell Lung Cancer Consumption by Country (2017-2022)

    • Figure United States Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)

    • Table Europe Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)

    • Figure China Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)

    • Figure Japan Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)

    • Figure India Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)

    • Figure South Korea Drugs for Non-small Cell Lung Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Drugs for Non-small Cell Lung Cancer Consumption Forecast by Country (2022-2028)

    • Figure United States Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Drugs for Non-small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Radiofrequency Ablation (RFA) Consumption and Growth Rate (2017-2022)

    • Figure Global Radiation Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Targeted Therapies Consumption and Growth Rate (2017-2022)

    • Figure Global Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Radiofrequency Ablation (RFA) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Targeted Therapies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Drugs for Non-small Cell Lung Cancer Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Drugs for Non-small Cell Lung Cancer Export by Region (Top 5 Countries) (2017-2028)

    • Table Menarini (Foundation Year, Company Profile and etc.)

    • Table Menarini Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Menarini Drugs for Non-small Cell Lung Cancer Product and Service

    • Table CytRx (Foundation Year, Company Profile and etc.)

    • Table CytRx Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table CytRx Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Exelixis (Foundation Year, Company Profile and etc.)

    • Table Exelixis Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Exelixis Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Apotex (Foundation Year, Company Profile and etc.)

    • Table Apotex Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Apotex Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Cerulean Pharma (Foundation Year, Company Profile and etc.)

    • Table Cerulean Pharma Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cerulean Pharma Drugs for Non-small Cell Lung Cancer Product and Service

    • Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Hikma Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Alchemia (Foundation Year, Company Profile and etc.)

    • Table Alchemia Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alchemia Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Cipla (Foundation Year, Company Profile and etc.)

    • Table Cipla Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cipla Drugs for Non-small Cell Lung Cancer Product and Service

    • Table CellAct Pharma (Foundation Year, Company Profile and etc.)

    • Table CellAct Pharma Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table CellAct Pharma Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Fresenius Kabi (Foundation Year, Company Profile and etc.)

    • Table Fresenius Kabi Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Fresenius Kabi Drugs for Non-small Cell Lung Cancer Product and Service

    • Table BioMarin Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Eli Lilly (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Amgen (Foundation Year, Company Profile and etc.)

    • Table Amgen Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Kyowa Hakko Kirin (Foundation Year, Company Profile and etc.)

    • Table Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Hospira (Foundation Year, Company Profile and etc.)

    • Table Hospira Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hospira Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Karyopharm Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Genentech (Foundation Year, Company Profile and etc.)

    • Table Genentech Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genentech Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Ligand Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Intas Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Curis (Foundation Year, Company Profile and etc.)

    • Table Curis Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Curis Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Ziopharm Oncology (Foundation Year, Company Profile and etc.)

    • Table Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Product and Service

    • Table Cornerstone Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US